Lp(a) lipoprotein level predicts survival and major corollary events in the Scandinavian Simvastatin Survival Study

Clinical Genetics

Volumn 52, Issue 5, 1997, Pages 254-261

  Berg, Kåre ^a   Dahlén, Gösta ^b   Christophersen, Bjoørn ^c   Cook, Thomas ^d   Kjekshus, John ^c   Pedersen, Terje ^e  

^a UNIVERSITY OF OSLO   (Norway)

^b UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d MERCK RESEARCH LABORATORIES   (United States)

^e AKER UNIVERSITY HOSPITAL   (Norway)

Author keywords

4S; Coronary death; Genetics; Lp(a) lipoprotein; Major coronary event; Prediction; Risk factor; Simvastatin

Indexed keywords

CHOLESTEROL; LIPOPROTEIN A; PLACEBO; SIMVASTATIN;

ADULT; AGED; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY RISK; DOUBLE BLIND PROCEDURE; HUMAN; ISCHEMIC HEART DISEASE; LIPOPROTEIN BLOOD LEVEL; LONG TERM CARE; MAJOR CLINICAL STUDY; MORTALITY; MULTICENTER STUDY; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCANDINAVIA; SURVIVAL;

EID: 0031409345     PISSN: 00099163     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-0004.1997.tb04342.x     Document Type: Conference Paper

References (22)

1. Berg K. A new serum type system in man - the Lp system. Acta Pathol Microbiol Scand 1963: 59: 369-382.
2. Berg K. Confounding results of Lp(a) lipoprotein measurements with some test kits. Clin Genet 1994: 46: 57-62.
3. Berg K. Lp(a) lipoprotein: an important genetic risk factor for atherosclerosis. In: Lusis AJ, Rotter JI, Sparkes RS, eds. Molecular genetics and coronary artery disease. Candidate genes and processes in atherosclerosis. Monogr. Hum. Genet. Basel: Karger, 1992: 189-207.
4. Berg K. Recent advances in the genetics of atherosclerosis. In: Woodford FP, Davignon J, Sniderman A, eds. Atherosclerosis. Amsterdam: Elsevier Science B.V., 1995: 610-613.
5. 1-lipoprotein in patients with coronary heart disease. Clin Genet 1974: 6: 230-235.
6. Berg K, Rø OC. Lp(a) lipoprotein level and longevity. Ann Génét 1991: 34: 264-269.
7. Bostom AG, Cupples A, Jenner JL, Ordovas JM Seman LJ, Wilson PWF, Schaefer EJ, Castelli WP. Elevated plasma lipoprotein (a) and coronary heart disease in men aged 55 years and younger. JAMA 1996: 276: 544-548.
8. Crow RS, Prineas RJ, Jacobs DR Jr, Blackburn H. A new epidemiologic classification system for interim myocardial infarction from serial electrocardiographic changes. Am J Cardiol 1989: 64: 454-461.
9. Dahlen GH. Incidence of Lp(a) lipoprotein among populations. In: Scanu AM, ed. Lipoprotein (a). San Diego: Academic Press, 1990: 151-173.
10. Djurovic S, Berg K. Epidemiology of Lp(a) lipoprotein: its role in atherosclerotic/thrombotic disease. Clin Genet 1997: 52: 295-306.
11. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972: 18: 499-502.
12. Jauhiainen M, Koskinen P, Ehnholm C, Frick MH, Manttari M, Manninen V, Huttunen JK. Lipoprotein (a) and coronary disease risk: a nested case-control study of the Helsinki Heart Study participants. Atherosclerosis 1991: 89: 59-67.
13. März W, Siekmeier RE, Gross W, Kostner GM. Determination of lipoprotein(a): evaluation of three methods. Eur J Clin Chem Clin Biochem 1993: 31: 295-301.
14. Pedersen TR, Kjekshus J, Berg K, Haghfelt T, Færgeman O, Thorgeirsson G, Pyörälä K, Miettinen T, Wilhelmsen L, Olsson AG, Wedel H. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994: 344: 1383-1389.
15. Rhoads GG, Dahlén G, Berg K, Morton NE, Dannenberg AL. Lp(a) lipoprotein as a risk factor for myocardial infarction. JAMA 1986: 256: 2540-2544.
16. Ridker PM, Hennekens CH, Stampfer MJ. A prospective study of lipoprotein(a) and the risk of myocardial infarction. JAMA 1993: 270: 2195-2199.
17. Rosengren A, Wilhelmsen L, Eriksson E, Risberg B, Wedel H. Lipoprotein(a) and coronary heart disease: a prospective case-control study in a general population sample of middle-aged men. BMJ 1990: 301: 1248-1251.
18. Scandinavian Simvastatin Survival Study Group. Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S). Lancet 1995: 345: 1274-1275.
19. Scandinavian Simvastatin Survival Study Group. Design and baseline results of the Scandinavian Simvastatin Study of patients with stable angina and or previous myocardial infarction. Am J Cardiol 1993: 71: 393-400.
20. Schäfer EJ, Lamon-Fava S, Jenner JL, McNamara JR, Ordovas JM, Davis Ce, Abolafia JM, Lippel K, Levy RI. Lipoprotein(a) levels and risk of coronary heart disease in men. JAMA 1994: 271: 999-1003.
21. Tuomilehto J, Arsitila M, Kaarsalo E, et al. Acute myocardial infarction in Finland: baseline data from the FINMONICA AMI register in 1983-85. Eur Heart J 1992: 13: 577-587.
22. WHO MONICA Project. MONICA manual revised edition. Geneva: Cardiovascular Diseases Unit, WHO, 1990.